Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral azacitidine versus placebo after allogeneic stem cell transplantation in AML and MDS
ISRCTN55111436Phase 3Active, not recruiting
- Sponsor
- University of Birmingham
- Start
- Jun 2019
- Modality
- Small Molecules, Drug Delivery Systems
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) comparing CC-486 with Placebo (2 arms). Primary endpoint: Relapse-free survival. Started Jun 2019; status: active, not recruiting.
02
Drugs
CC-486
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ISRCTN55111436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN55111436.